Allarity TherapeuticsALLR
About: Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
Employees: 6
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
823% more capital invested
Capital invested by funds: $11.7K [Q1] → $108K (+$96.1K) [Q2]
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
125% more funds holding
Funds holding: 4 [Q1] → 9 (+5) [Q2]
1.37% more ownership
Funds ownership: 0.63% [Q1] → 1.99% (+1.37%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for ALLR.
Financial journalist opinion
Based on 117 articles about ALLR published over the past 30 days